Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABL Bio Corp.

http://www.ablbio.com

Latest From ABL Bio Corp.

Q2 Korean Biotech Roundup: Partners Return Multiple Assets

The second quarter in South Korea was marked by the return of several assets by licensing partners, including Thea Open Innovation, which gave back rights to two ophthalmic programs in-licensed from OliX. Merck & Co. also cancelled a co-research deal with Artiva Biotherapeutics.

South Korea Deals

Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA

Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet

Deal Watch Business Strategies

Korea 2024 Outlook: Continued Focus On Drug Delivery Technologies

In a tough R&D environment, delivery technology-based new drug development activities by Korean firms are poised to remain robust in 2024.

South Korea Drug Delivery Technology

Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy

Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register